Stock Research for BPTH

BPTH

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BPTH Stock Chart & Research Data

The BPTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BPTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BPTH Due diligence Resources & Stock Charts

The BPTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BPTH Detailed Price Forecast - CNN Money CNN View BPTH Detailed Summary - Google Finance
Yahoo View BPTH Detailed Summary - Yahoo! Finance Zacks View BPTH Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BPTH Trends & Analysis - Trade-Ideas Barrons View BPTH Major Holders - Barrons
NASDAQ View BPTH Call Transcripts - NASDAQ Seeking View BPTH Breaking News & Analysis - Seeking Alpha
Spotlight View BPTH Annual Report - CompanySpotlight.com OTC Report View BPTH OTC Short Report - OTCShortReport.com
TradeKing View BPTH Fundamentals - TradeKing Charts View BPTH SEC Filings - Bar Chart
WSJ View Historical Prices for BPTH - The WSJ Morningstar View Performance/Total Return for BPTH - Morningstar
MarketWatch View the Analyst Estimates for BPTH - MarketWatch CNBC View the Earnings History for BPTH - CNBC
StockMarketWatch View the BPTH Earnings - StockMarketWatch MacroAxis View BPTH Buy or Sell Recommendations - MacroAxis
Bullish View the BPTH Bullish Patterns - American Bulls Short Pains View BPTH Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BPTH Stock Mentions - StockTwits PennyStocks View BPTH Stock Mentions - PennyStockTweets
Twitter View BPTH Stock Mentions - Twitter Invest Hub View BPTH Investment Forum News - Investor Hub
Yahoo View BPTH Stock Mentions - Yahoo! Message Board Seeking Alpha View BPTH Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BPTH - SECform4.com Insider Cow View Insider Transactions for BPTH - Insider Cow
CNBC View BPTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BPTH - OTC Markets
Yahoo View Insider Transactions for BPTH - Yahoo! Finance NASDAQ View Institutional Holdings for BPTH - NASDAQ


Stock Charts

FinViz View BPTH Stock Insight & Charts - FinViz.com StockCharts View BPTH Investment Charts - StockCharts.com
BarChart View BPTH Stock Overview & Charts - BarChart Trading View View BPTH User Generated Charts - Trading View




Latest Financial News for BPTH


Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Posted on Friday April 19, 2024

HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 375,000 shares of its common stock at a purchase price of $3.225 per share and c


Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Posted on Friday April 19, 2024

Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.


Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Posted on Thursday April 18, 2024

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it has entered into a definitive agreement with certain institutional investors for the issuance and sale of 375,000 shares of its common stock at a purchase price per share of $3.225 in a registered d


Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients
Posted on Thursday April 18, 2024

BP1002 Offers Unique Opportunity for Venetoclax-Resistant AML Patients Utilizing RNAi to Limit AML Cell’s Ability to Produce Cancer Enabling Bcl-2 ProteinHOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/


Stock Market & Investing Books

Enter a stock symbol to view the stock details.